Suppr超能文献

基线卡氏功能状态可独立预测转移性疾病颅内放射治疗完成后30天内的死亡情况。

Baseline Karnofsky performance status is independently predictive of death within 30 days of intracranial radiation therapy completion for metastatic disease.

作者信息

McClelland Iii Shearwood, Agrawal Namita, Elbanna May F, Shiue Kevin, Bartlett Gregory K, Lautenschlaeger Tim, Zellars Richard C, Watson Gordon A, Ellsworth Susannah G

机构信息

Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, United States.

出版信息

Rep Pract Oncol Radiother. 2020 Jul-Aug;25(4):698-700. doi: 10.1016/j.rpor.2020.02.014. Epub 2020 Feb 24.

Abstract

INTRODUCTION

For patients with brain metastases, palliative radiation therapy (RT) has long been a standard of care for improving quality of life and optimizing intracranial disease control. The duration of time between completion of palliative RT and patient death has rarely been evaluated.

METHODS

A compilation of two prospective institutional databases encompassing April 2015 through December 2018 was used to identify patients who received palliative intracranial radiation therapy. A multivariate logistic regression model characterized patients adjusting for age, sex, admission status (inpatient versus outpatient), Karnofsky Performance Status (KPS), and radiation therapy indication.

RESULTS

136 consecutive patients received intracranial palliative radiation therapy. Patients with baseline KPS <70 (OR = 2.2; 95%CI = 1.6-3.1;  < 0.0001) were significantly more likely to die within 30 days of treatment. Intracranial palliative radiation therapy was most commonly delivered to provide local control (66% of patients) or alleviate neurologic symptoms (32% of patients), and was most commonly delivered via whole brain radiation therapy in 10 fractions to 30 Gy (38% of patients). Of the 42 patients who died within 30 days of RT, 31 (74%) received at least 10 fractions.

CONCLUSIONS

Our findings indicate that baseline KPS <70 is independently predictive of death within 30 days of palliative intracranial RT, and that a large majority of patients who died within 30 days received at least 10 fractions. These results indicate that for poor performance status patients requiring palliative intracranial radiation, hypofractionated RT courses should be strongly considered.

摘要

引言

对于脑转移瘤患者,姑息性放射治疗(RT)长期以来一直是改善生活质量和优化颅内疾病控制的标准治疗方法。姑息性RT完成至患者死亡之间的时间间隔很少被评估。

方法

使用两个前瞻性机构数据库(涵盖2015年4月至2018年12月)的汇总数据来识别接受姑息性颅内放射治疗的患者。一个多变量逻辑回归模型对患者进行了特征分析,对年龄、性别、入院状态(住院患者与门诊患者)、卡氏功能状态(KPS)和放射治疗指征进行了调整。

结果

136例连续患者接受了颅内姑息性放射治疗。基线KPS<70的患者(OR = 2.2;95%CI = 1.6 - 3.1;<0.0001)在治疗后30天内死亡的可能性显著更高。颅内姑息性放射治疗最常用于提供局部控制(66%的患者)或缓解神经症状(32%的患者),最常见的是通过全脑放射治疗,分10次给予30 Gy(38%的患者)。在RT后30天内死亡的42例患者中,31例(74%)接受了至少10次分割。

结论

我们的研究结果表明,基线KPS<70可独立预测姑息性颅内RT后30天内的死亡,并且在30天内死亡的患者中,绝大多数接受了至少10次分割。这些结果表明,对于需要姑息性颅内放射治疗的功能状态较差的患者,应强烈考虑采用低分割RT疗程。

相似文献

1
2
Clinical Factors Associated With 30-Day Mortality Among Patients Undergoing Radiation Therapy for Brain Metastases.
Adv Radiat Oncol. 2023 Mar 8;8(4):101211. doi: 10.1016/j.adro.2023.101211. eCollection 2023 Jul-Aug.
6
Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making.
Adv Radiat Oncol. 2018 Sep 14;4(1):127-133. doi: 10.1016/j.adro.2018.09.002. eCollection 2019 Jan-Mar.
8
Patterns of palliative radiotherapy fractionation for brain metastases patients in New South Wales, Australia.
Radiother Oncol. 2021 Mar;156:174-180. doi: 10.1016/j.radonc.2020.12.020. Epub 2020 Dec 24.
9
Patterns of care among patients receiving radiation therapy for bone metastases at a large academic institution.
Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1100-1105. doi: 10.1016/j.ijrobp.2014.04.028. Epub 2014 Jul 8.
10
Preventing Discontinuation of Radiation Therapy: Predictive Factors to Improve Patient Selection for Palliative Treatment.
J Oncol Pract. 2017 Sep;13(9):e782-e791. doi: 10.1200/JOP.2017.021220. Epub 2017 Jul 31.

引用本文的文献

1
Clinical Factors Associated With 30-Day Mortality Among Patients Undergoing Radiation Therapy for Brain Metastases.
Adv Radiat Oncol. 2023 Mar 8;8(4):101211. doi: 10.1016/j.adro.2023.101211. eCollection 2023 Jul-Aug.
2
The utility of F-FDG PET/CT in brain tumours diagnosis.
Rep Pract Oncol Radiother. 2022 May 19;27(2):235-240. doi: 10.5603/RPOR.a2022.0021. eCollection 2022.
3
Brain metastases from non-small cell lung carcinoma: an overview of classical and novel treatment strategies.
Rep Pract Oncol Radiother. 2022 Jul 29;27(3):527-544. doi: 10.5603/RPOR.a2022.0050. eCollection 2022.
4
Quality of Life and Role of Palliative and Supportive Care for Patients With Brain Metastases and Caregivers: A Review.
Front Neurol. 2022 Feb 17;13:806344. doi: 10.3389/fneur.2022.806344. eCollection 2022.

本文引用的文献

1
Nearly Half of Metastatic Brain Disease Patients Prescribed 10 Fractions of Whole-Brain Radiation Therapy Die Without Completing Treatment.
J Pain Symptom Manage. 2019 Aug;58(2):e5-e6. doi: 10.1016/j.jpainsymman.2019.04.022. Epub 2019 Apr 25.
2
Epidemiology, Treatment, and Complications of Central Nervous System Metastases.
Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1580-1600. doi: 10.1212/CON.0000000000000551.
4
Whole-brain radiotherapy in the management of brain metastasis.
J Clin Oncol. 2006 Mar 10;24(8):1295-304. doi: 10.1200/JCO.2005.04.6185.
5
Roentgen-ray therapy of cerebral metastases.
Cancer. 1954 Jul;7(4):682-9. doi: 10.1002/1097-0142(195407)7:4<682::aid-cncr2820070409>3.0.co;2-s.
6
Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51. doi: 10.1016/s0360-3016(96)00619-0.
8
The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group.
Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):1-9. doi: 10.1016/0360-3016(80)90195-9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验